RxDoctor Payments Data

Troy Sukkarieh, MD

Urology · Freehold, NJNPI 1003913815

Payments from drug & device makers

$394in general payments, 2019–2025

Across 16 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$174
  • Medtronic$74
  • Procept Biorobotics Corporation$31
  • Ferring Pharmaceuticals Inc.$22
  • Rochester Medical Corporation$16
  • Pfizer$15
  • plus $63 from 5 others

What the payments were for

  • Food & beverage$37996%
  • Education$154%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$394 in reported general payments places this provider in the 20th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$876,866
Medicare patients
2,009
Services billed
23,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide28$401,459
NubeqaDarolutamide12$163,716
Abiraterone Acetate25$107,402
MyrbetriqMirabegron70$76,081
Tamsulosin Hcl1,190$21,039
Finasteride1,080$14,319
Dutasteride228$11,596
Potassium Citrate ErPotassium Citrate51$7,195
Darifenacin ErDarifenacin Hydrobromide23$5,776
GemtesaVibegron12$5,735
Tolterodine Tartrate ErTolterodine Tartrate60$4,279
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl14$4,115
Alfuzosin Hcl ErAlfuzosin Hcl156$4,041
Silodosin31$3,794
Oxybutynin Chloride ErOxybutynin Chloride161$3,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$13$477,54098 claims
BayerNubeqa$13$163,71612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 401 urology providers in New Jersey.

Other urology in Freehold

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →